Iveta Kudaba - Concepedia

Author

Iveta Kudaba

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

I. Kudaba, Iveta Kudaba

Publications

12.5K

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)Yonsei University Riga East University Hospital Instituto do Câncer do Estado de São Paulo The Maria Sklodowska-Curie National Research Institute of Oncology

About

Iveta Kudaba is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	4.4K
2	Pathology	10	10	4.4K
3	Health Sciences	5	5	1.3K
4	Gastroenterology	3	3	212
5	Immunology	2	2	51

Iveta Kudaba

Publications

9.3K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial Tony Mok, Yi‐Long Wu, Iveta Kudaba, The Lancet	2019	3.2K
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study Barbara Burtness, Kevin J. Harrington, Richard Greil, The Lancet Neoadjuvant TherapyChemotherapy Versus CetuximabMedicinePathologyHead And Neck Cancer	2019	3K
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer Kohei Shitara, Eric Van Cutsem, Yung‐Jue Bang, JAMA Oncology	2020	1.1K
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study Sandra M. Swain, David Miles, Sung‐Bae Kim, The Lancet Oncology End-of-study ResultsBreast OncologyMedicineClinical TrialsPathology	2020	854
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study Gilberto de Castro, Iveta Kudaba, Yi‐Long Wu, Journal of Clinical Oncology	2022	281
Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study. Gilberto Lopes, Yi‐Long Wu, Iveta Kudaba, Journal of Clinical Oncology Optional Peme MaintenanceKeynote-042 StudyPeme MaintenanceMedicinePharmacology	2018	192
Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study. Josep Tabernero, Eric Van Cutsem, Yung‐Jue Bang, Journal of Clinical Oncology Esophageal CancerLba4007 BackgroundP+c Vs CGastroenterologyPathology	2019	167
Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study Keun‐Wook Lee, Eric Van Cutsem, Yung‐Jue Bang, Clinical Cancer Research	2022	81
Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive‐stage small cell lung cancer: A multicentre, randomised, double‐blind, placebo‐controlled Phase <scp>II</scp> trial Davey B. Daniel, Vladimer Kuchava, Igor Bondarenko, International Journal of Cancer	2020	78
Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1–positive locally advanced/metastatic NSCLC Tony Mok, Yi‐Long Wu, Iveta Kudaba, Annals of Oncology	2019	38

Page 1